Business
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir Preclinical Animal Data
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nPhase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir\n\n\nPreclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household Transmission and to Minimize SARS-CoV-2 Rebound\n\n\nHigh Throughput Screen Identifies Non-Nucleoside Small Molecule Inhibitors of the SARS-CoV-2 RNA-Dependent RNA Polymerase\n\n\n WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced new data supporting the potential of EDP-235 for the treatment of COVID-19, which are being presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre de Congrès de Lyon (Lyon Convention Center) in Lyon, France. The company will have one oral presentation and three poster presentations, showcasing the potential of EDP-235 and Enanta’s leadership in the development of small molecules for the treatment of viral respiratory infections.\n\nPhase 1 data presented continue to highlight EDP-235’s promising overall safety, tolerability and pharmacokinetic (PK) profile, and preclinical data demonstrate EDP-235’s ability to suppress viral replication and transmission in an animal model. Additional preclinical data show EDP-235’s targeted tissue penetration and potential to mitigate rebound in COVID-19 patients. A fourth presentation focuses on a high-throughput screen to identify non-nucleoside inhibitors of the RNA-dependent RNA polymerase. EDP-235 is currently being evaluated in SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 study of non-hospitalized, symptomatic adults with mild or moderate COVID-19, and has a data readout targeted for May 2023.\n\n“We are excited to present new clinical and preclinical data which continue to add to the robust findings supporting the potential of EDP-235 as a differentiated, once-daily, oral treatment for patients with COVID-19, as well as to demonstrate our broad capabilities in developing small molecules against this virus,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Findings from our Phase 1 study continue to show EDP-235’s favorable safety, tolerability and pharmacokinetics with strong exposur...